摘要
近年来,多重耐药细菌特别是碳青霉烯类耐药革兰阴性菌(如碳青霉烯耐药肠杆菌)的高感染率和高死亡率已成为全球性的公共卫生危机。头孢他啶/阿维巴坦是第三代头孢菌素类药物和新型非β-内酰胺类β-内酰胺酶抑制剂的混合制剂,能抑制大部分碳青霉烯酶,治疗碳青霉烯耐药革兰阴性菌感染的疗效显著且耐受性好。本综述主要总结头孢他啶/阿维巴坦的药学特性、治疗碳青霉烯耐药革兰阴性菌的疗效、安全性和耐药情况,以期为临床科学使用头孢他啶/阿维巴坦提供理论基础,促进合理用药。
Recently, the wide and rapid prevalence of multidrug resistant bacteria has become a global public health crisis, especially both the infection incidence and mortality rate of Carbapenem-resistant Gram-negative bacteria are relatively high. Ceftazidime/avibactam is a mixture of the third generation cephalosporins and a new type of non-β-lactam β-lactamase inhibitor. Due to prominent efficiency and good tolerance, it is considered as a promising drug for the treatment of infection induced by Carbapenem-resistant Gram-negative bacteria. This review mainly summarizes the pharmaceutical characteristics, efficacy, safety and resistance of ceftazidime-avibactam in the treatment of Carbapenem-resistant Gram-negative bacteria. We expect our review will provide theoretical basis for scientific application of ceftazidime/avibactam in the therapy of infection induced by Carbapenem-resistant Gramnegative bacteria and will promote rational drug usage in clinic.
作者
李慧
刘莉群
秦丹
靳洪涛
卞晓岚
Li Hui;Liu Li-qun;Qin Dan;Jin Hong-tao;Bian Xiao-Lan(Department of Pharmacy,Ruijin Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200025;First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 250355;Research Center of TCM-Infbrmation Engineering,School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102488;New Drug Safety Evaluation Center,Institute of Materia Medica,Chinese Academy of Medical Sciences,Beijing 100050;Beijing Union-Genious Pharmaceutical Technology Ltd.,Beijing 100176)
基金
国家重点研发计划资助(2020YFC2008305)。
